Dann Rebecca Byler, Kelley Joseph L, Zorn Kristin K
Division of Gynecologic Oncology, Department of Obstetrics, Magee Womens Hospital of the University of Pittsburgh Medical Center, 300 Halket Street, Pittsburgh, PA 15213, USA.
Obstet Gynecol Clin North Am. 2007 Dec;34(4):667-86, viii. doi: 10.1016/j.ogc.2007.10.001.
Women who have documented BRCA1 or BRCA2 mutations have a significantly increased lifetime risk of ovarian and breast malignancies. Many women, however, have a perceived personal risk of ovarian cancer despite a calculated low risk, and some seek ways to reduce the risk for ovarian cancer. Given the low prevalence of ovarian cancer in the general population, no screening test has achieved satisfactory levels of disease prediction. This article discusses the efficacy of available screening modalities and reviews current risk-reduction strategies and their effectiveness for preventing ovarian cancer.
已记录有BRCA1或BRCA2基因突变的女性一生中患卵巢癌和乳腺癌的风险显著增加。然而，许多女性尽管经计算患卵巢癌的风险较低，但仍自认为有患卵巢癌的个人风险，一些人寻求降低卵巢癌风险的方法。鉴于卵巢癌在普通人群中的患病率较低，尚无筛查测试能达到令人满意的疾病预测水平。本文讨论了现有筛查方式的有效性，并综述了当前的风险降低策略及其预防卵巢癌的效果。
